drugset / Trial / NCT00478634
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Timeline
- Start
- 2007-05
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Everolimus | Small molecule | 30 mg | Oral |
| Subject | Irinotecan | Small molecule | 250 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 350 mg/m2 | Intravenous |